2Ciardella A P, Klancnik J.Intravitreal triamcinolone for the treatment of rctory diahetic macnl edergg hgrd dte an optical coherence to mography [J].J Bhhlmol, 2004, 88 (9): 1131-1136.
3Parodi M B, Saviano lgvgtreatment in macular branch retinal veiUaio[J].Oreases Arch Clin Exp Ophthalmol, 1999, 237 (12) : 1024-1027.
4Gillies M C, Simpson J M, Billson F A, et al.Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial[J1,Ateh Oplahalmol, 2004, 122 ( 3 ) : 336-340.
5Li X, X G, Wang Y, et al.Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study[J]. Ophthalmology, 2014, 121 ( 9 ).: 1740-1747.
6Campochiaro P A, Sophie R, Pearlman J, et al.Long- termoutcomes in patients with retinal retinal vein occlusion treated with ranibizumab: the RETAIN study[J].Ophthalm01ogy, 2014, 121 ( 1 ) : 209-219.
7Brown D M, Heier J S, Clark W L, et al.lntravitreal aflibercept injection for macular edema secondary to central retinal vein occlusioyear results from the phase 3 COPERNICUS aludy[J],Am J Ophthalmol, 2013, 155 ( 3 ) : 429-437.
8Ogura Y, Roider J, Korobelnik J F, et al.Intravitreal allibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study[J]. Am J Ophthalmol, 2014, 158 (5) : 1032-1038.
9Thach A B, Yau L, Hoang C, et al.Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion:BRAVO and CRUISE trials[J]. Ophthalmology, 2014, 121 ( 5 ) : 1059-1066.
